Over the last 7 days, the Australian market has risen 2.1%, driven by gains in every sector, and it is up 13% over the last 12 months with earnings forecast to grow by 12% annually. In this thriving environment, growth companies with high insider ownership can be particularly attractive as they often indicate strong confidence from those who know the business best.
Top 10 Growth Companies With High Insider Ownership In Australia
| Name | Insider Ownership | Earnings Growth |
| Clinuvel Pharmaceuticals (ASX:CUV) | 10.4% | 27.4% |
| Catalyst Metals (ASX:CYL) | 17% | 54.5% |
| Genmin (ASX:GEN) | 12% | 117.7% |
| Hillgrove Resources (ASX:HGO) | 10.4% | 70.9% |
| AVA Risk Group (ASX:AVA) | 15.7% | 118.8% |
| Pointerra (ASX:3DP) | 18.7% | 126.4% |
| Liontown Resources (ASX:LTR) | 16.4% | 69.4% |
| Acrux (ASX:ACR) | 17.4% | 91.6% |
| Adveritas (ASX:AV1) | 21.1% | 144.2% |
| Plenti Group (ASX:PLT) | 12.8% | 106.4% |
Here we highlight a subset of our preferred stocks from the screener.
APM Human Services International (ASX:APM)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: APM Human Services International Limited (ASX:APM) offers human and health services, with a market cap of A$1.33 billion.
Operations: The company's revenue segments are A$839.85 million from ANZ (Australia and New Zealand), A$1.07 billion from North America (Canada and the USA), and A$385.38 million from the Rest of World (Korea, Singapore, Germany, Switzerland, Spain, and the UK).
Insider Ownership: 27.2%
Earnings Growth Forecast: 55.6% p.a.
APM Human Services International is forecast to become profitable within three years, with earnings expected to grow at 55.58% annually. Despite trading at a significant discount to its estimated fair value, the company faces challenges including recent delisting from OTC equity due to inactivity and a net loss of A$220.74 million for FY2024. Revenue growth is projected at 6.2% per year, outpacing the broader Australian market but below high-growth benchmarks.
- Click here and access our complete growth analysis report to understand the dynamics of APM Human Services International.
- The analysis detailed in our APM Human Services International valuation report hints at an deflated share price compared to its estimated value.
Guzman y Gomez (ASX:GYG)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Guzman y Gomez Limited owns, operates, and franchises quick service restaurants in Australia, Singapore, Japan, and the United States with a market cap of A$4.13 billion.
Operations: The company generates revenue primarily from its restaurants, amounting to A$364.99 million.
Insider Ownership: 14.2%
Earnings Growth Forecast: 47.3% p.a.
Guzman y Gomez Limited reported A$342.21 million in sales for FY2024, up from A$259.04 million the previous year, but net loss widened to A$13.75 million from A$2.27 million. Despite current losses, revenue is forecast to grow 17.7% annually, outpacing the Australian market's 5.4% growth rate and earnings are expected to increase by 47.31% per year with profitability anticipated within three years, indicating strong growth potential amidst high insider ownership.
- Dive into the specifics of Guzman y Gomez here with our thorough growth forecast report.
- The valuation report we've compiled suggests that Guzman y Gomez's current price could be inflated.
Mesoblast (ASX:MSB)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Mesoblast Limited develops regenerative medicine products across Australia, the United States, Singapore, and Switzerland, with a market cap of A$11.13 billion.
Operations: Mesoblast Limited's revenue primarily comes from the development of its cell technology platform for commercialization, amounting to $5.90 million.
Insider Ownership: 22.2%
Earnings Growth Forecast: 59.1% p.a.
Mesoblast Limited, a biopharmaceutical company with significant insider ownership, recently reported a net loss of US$87.96 million for FY2024, up from US$81.89 million the previous year, despite sales of US$5.9 million. The company's lead product candidate, Ryoncil (remestemcel-L), has received FDA acceptance for its Biologics License Application resubmission and is anticipated to see a decision by January 2025. Mesoblast's revenue is forecast to grow at 46.9% annually with profitability expected within three years.
- Get an in-depth perspective on Mesoblast's performance by reading our analyst estimates report here.
- According our valuation report, there's an indication that Mesoblast's share price might be on the cheaper side.
Seize The Opportunity
- Get an in-depth perspective on all 99 Fast Growing ASX Companies With High Insider Ownership by using our screener here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About ASX:MSB
Mesoblast
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
High growth potential and good value.
